Investor Presentaiton
Strong business momentum
Diversified portfolio growth
Efficient compounding engine
Sustainable long-term growth
Long-term growth powered by consistent portfolio replenishment
Adjusted Cash Receipts (1) (2) ("top-line")
13% CAGR
Unusual period with 4 large royalty
expirations: Tecfidera, Remicade,
Humira, and Lyrica totaling >$1bn in
adjusted cash receipts
11-14% CAGR
10%+ CAGR
2010
2018
2020
2025e
Pre-2010
2010-2012
2013-2015
2016-2018
2019-2021
2022-2024
2025-2027
2028-2030
Current portfolio
Future royalty acquisitions(3)
ROYALTY PHARMA
1. Adjusted Cash Receipts for periods 2020 and earlier are pro forma for current non-controlling interests. See footnote (1) on slide 114 for additional information.
2. See slide 114 for definitions and factors that may impact the achievement of our growth outlook. Growth outlook includes future royalty acquisitions and excludes development-stage pipeline
candidate gantenerumab for Alzheimer's disease. Refer to the Appendix for a GAAP to non-GAAP reconciliation.
3. Illustrative analysis calculated using representative cash receipts based on blended average of actual and projected returns for approved and development-stage transactions over the last five
years under a range of scenarios. Assumes $2.0-2.5bn of capital deployed on average per year through 2030.
2030e
102View entire presentation